What happens when tau tangles?

Tau’s usual role is to stabilize microtubules in healthy neurons and help maintain axonal structure³. However, in disease, tau undergoes hyperphosphorylation, detaches from microtubules, and begins to misfold⁴. These misfolded forms aggregate into paired helical filaments, which clump into neurofibrillary tangles.

Worse still, misfolded tau can spread between neurons, seeding other tau molecules to misfold⁵. This prion-like propagation is thought to drive the stereotyped progression of tau pathology through the brain, from the entorhinal cortex to the hippocampus and into broader cortical regions⁶. It’s a loss of function and a gain of toxicity—all in one molecule.

From amyloid-first thinking to tau-first strategies

For decades, the amyloid cascade hypothesis dominated Alzheimer’s research⁷. According to this model, amyloid-β accumulation comes first, triggering tau pathology and ultimately causing neuronal death⁸. But disappointing results from amyloid-targeting drugs have led to a shift⁹.

Increasingly, researchers see tau tangles as not just a downstream consequence of amyloid, but as active drivers of neurodegeneration¹⁰. In fact, some studies suggest that once tau pathology is established, it continues to spread even if amyloid plaques are cleared. That doesn’t make amyloid irrelevant, but it does suggest that future therapies may need to target both proteins in parallel to slow or halt cognitive decline.

How researchers are studying tau

As tau has moved into focus, so have the tools to study it. Here are three key technologies making a difference:

Conformation-specific antibodies

Rather than targeting total tau, researchers are using antibodies that recognize specific pathological conformations¹¹. These tools distinguish between healthy and disease-associated forms of tau, enabling more precise studies of tau species in different stages of disease or across tauopathies.

Tau seeding assays

Biosensor cell lines that fluoresce in response to tau aggregation have transformed how we study its propagation¹². These assays detect prion-like “seeding” activity in CSF or brain homogenates and are increasingly used to compare tau strains across diseases like AD, PSP, and frontotemporal dementia, or to screen small molecules that block tau spread.

In vivo tau imaging

PET tracers like [¹⁸F]flortaucipir (Tauvid™) allow direct visualization of aggregated tau in living patients^13,14. These tools are revolutionizing research in clinical diagnostics and trials by tracking tau burden over time, stratifying participants, and evaluating treatment efficacy.

Tau-targeted therapies on the horizon

With tau recognized as a driver of disease, multiple therapeutic strategies are under investigation:

• Antisense oligonucleotides (ASOs): These RNA-like molecules reduce tau production by degrading mRNA. Early trials show promise in lowering CSF tau levels, though long-term cognitive effects remain to be seen¹⁵.

• Monoclonal antibodies: These are designed to bind to extracellular tau, or in some cases, enter cells, to neutralize or clear pathological forms. First-generation antibodies have underwhelmed in trials, but newer constructs offer improved target specificity and brain penetration¹⁶.

• Kinase inhibitors, aggregation blockers, and stabilizers: Strategies targeting tau kinases (to prevent hyperphosphorylation), inhibiting aggregation, or stabilizing microtubules are also advancing through preclinical and early clinical stages^17,18.

Researchers are hoping for additive or synergistic benefits by combining tau therapies with anti-amyloid agents, offering new opportunities in AD treatment.

Tau as a biomarker

Tau’s role in Alzheimer’s extends beyond pathology—it’s also a powerful biomarker. CSF phospho-tau (such as pTau181 and pTau217) is already used in diagnostic workflows, often alongside amyloid-β and neurodegeneration markers in the A/T/N framework¹⁹, and plasma assays for phospho-tau are rapidly improving, correlating strongly with tau PET imaging and disease progression²⁰. Researchers are also investigating emerging markers like MTBR-tau243, which measures fragments from tau’s microtubule-binding region²¹. These new markers may provide more direct insight into insoluble, aggregated tau and complement existing pTau readouts.

Why tau research matters

Even if you’re not working directly on AD, tau tangles are increasingly relevant across research settings, including:

• Other tauopathies, such as frontotemporal dementia, progressive supranuclear palsy, and chronic traumatic encephalopathy, all involve abnormal tau.

• In vitro models that involve stress, inflammation, or aging often show tau-related phenotypes, even unintentionally.

• Biomarker and imaging work is increasingly tau-inclusive, and understanding tau’s behavior can help explain signal variability or off-target effects.

If you’re using antibodies, iPSC-derived neurons, or imaging platforms, you’re likely to encounter tau as a signal or source of unexpected variability. Understanding how it behaves and how the field is evolving means designing cleaner experiments and asking better questions in your own work.

References

1. Tepper, K.; Biernat, J.; Kumar, S.; Wegmann, S.; Timm, T.; Hübschmann, S.; Redecke, L.; Mandelkow, E.-M.; Müller, D. J.; Mandelkow, E. Oligomer Formation of Tau Protein Hyperphosphorylated in Cells*. J. Biol. Chem. 2014, 289 (49), 34389–34407. https://doi.org/10.1074/jbc.M114.611368.
2. Luo, Y.; Yu, H.; Ye, K. Distinct Factors Drive the Progression of Tau Pathology in Alzheimer’s Disease. Fundam. Res. 2025. https://doi.org/10.1016/j.fmre.2025.04.001.
3. Barbier, P.; Zejneli, O.; Martinho, M.; Lasorsa, A.; Belle, V.; Smet-Nocca, C.; Tsvetkov, P. O.; Devred, F.; Landrieu, I. Role of Tau as a Microtubule-Associated Protein: Structural and Functional Aspects. Front. Aging Neurosci. 2019, 11. https://doi.org/10.3389/fnagi.2019.00204.
4. Moore, K. B. E.; Hung, T.-J.; Fortin, J. S. Hyperphosphorylated Tau (p-Tau) and Drug Discovery in the Context of Alzheimer’s Disease and Related Tauopathies. Drug Discov. Today 2023, 28 (3), 103487. https://doi.org/10.1016/j.drudis.2023.103487.
5. Mudher, A.; Colin, M.; Dujardin, S.; Medina, M.; Dewachter, I.; Alavi Naini, S. M.; Mandelkow, E.-M.; Mandelkow, E.; Buée, L.; Goedert, M.; Brion, J.-P. What Is the Evidence That Tau Pathology Spreads through Prion-like Propagation? Acta Neuropathol. Commun. 2017, 5 (1), 99. https://doi.org/10.1186/s40478-017-0488-7.
6. Pooler, A. M.; Polydoro, M.; Wegmann, S.; Nicholls, S. B.; Spires-Jones, T. L.; Hyman, B. T. Propagation of Tau Pathology in Alzheimer’s Disease: Identification of Novel Therapeutic Targets. Alzheimers Res. Ther. 2013, 5 (5), 49. https://doi.org/10.1186/alzrt214.
7. Behl, C. In 2024, the Amyloid-Cascade-Hypothesis Still Remains a Working Hypothesis, No Less but Certainly No More. Front. Aging Neurosci. 2024, 16. https://doi.org/10.3389/fnagi.2024.1459224.
8. Barage, S. H.; Sonawane, K. D. Amyloid Cascade Hypothesis: Pathogenesis and Therapeutic Strategies in Alzheimer’s Disease. Neuropeptides 2015, 52, 1–18. https://doi.org/10.1016/j.npep.2015.06.008.
9. Kepp, K. P.; Robakis, N. K.; Høilund-Carlsen, P. F.; Sensi, S. L.; Vissel, B. The Amyloid Cascade Hypothesis: An Updated Critical Review. Brain 2023, 146 (10), 3969–3990. https://doi.org/10.1093/brain/awad159.
10. Bilgel, M.; Wong, D. F.; Moghekar, A. R.; Ferrucci, L.; Resnick, S. M.; the Alzheimer’s Disease Neuroimaging Initiative. Causal Links among Amyloid, Tau, and Neurodegeneration. Brain Commun. 2022, 4 (4), fcac193. https://doi.org/10.1093/braincomms/fcac193.
11. Gibbons, G. S.; Kim, S.-J.; Wu, Q.; Riddle, D. M.; Leight, S. N.; Changolkar, L.; Xu, H.; Meymand, E. S.; O’Reilly, M.; Zhang, B.; Brunden, K. R.; Trojanowski, J. Q.; Lee, V. M. Y. Conformation-Selective Tau Monoclonal Antibodies Inhibit Tau Pathology in Primary Neurons and a Mouse Model of Alzheimer’s Disease. Mol. Neurodegener. 2020, 15 (1), 64. https://doi.org/10.1186/s13024-020-00404-5.
12. Lathuiliere, A.; Jo, Y.; Perbet, R.; Donahue, C.; Commins, C.; Quittot, N.; Fan, Z.; Bennett, R. E.; Hyman, B. T. Specific Detection of Tau Seeding Activity in Alzheimer’s Disease Using Rationally Designed Biosensor Cells. Mol. Neurodegener. 2023, 18 (1), 53. https://doi.org/10.1186/s13024-023-00643-2.
13. Tian, M.; Civelek, A. C.; Carrio, I.; Watanabe, Y.; Kang, K. W.; Murakami, K.; Garibotto, V.; Prior, J. O.; Barthel, H.; Zhou, R.; Hou, H.; Dou, X.; Jin, C.; Zuo, C.; Zhang, H.; Molecular Imaging-based Precision Medicine Task Group of A3 (China-Japan-Korea) Foresight Program. International Consensus on the Use of Tau PET Imaging Agent 18F-Flortaucipir in Alzheimer’s Disease. Eur. J. Nucl. Med. Mol. Imaging 2022, 49 (3), 895–904. https://doi.org/10.1007/s00259-021-05673-w.
14. First Tau Imaging Agent for Alzheimer Disease FDA-Approved. Neurology live. https://www.neurologylive.com/view/flortaucipir-pet-tracer-approved-as-first-tau-imaging-agent-for-alzheimer-disease (accessed 2025-07-18).
15. Edwards, A. L.; Collins, J. A.; Junge, C.; Kordasiewicz, H.; Mignon, L.; Wu, S.; Li, Y.; Lin, L.; DuBois, J.; Hutchison, R. M.; Ziogas, N.; Shulman, M.; Martarello, L.; Graham, D.; Lane, R.; Budd Haeberlein, S.; Beaver, J. Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2023, 80 (12), 1344–1352. https://doi.org/10.1001/jamaneurol.2023.3861.
16. Song, H.-L.; Kim, M.-S.; Cho, W.-Y.; Yoo, Y.-S.; Kim, J.-Y.; Kim, T.-W.; Kim, H.; Kim, D.-H.; Yoon, S.-Y. Comparing Anti-Tau Antibodies under Clinical Trials and Their Epitopes on Tau Pathologies. Mol. Neurodegener. 2024, 19 (1), 76. https://doi.org/10.1186/s13024-024-00769-x.
17. Su, J.; Xiao, Y.; Wang, X.; Zheng, J.; Wang, J.-Z. Development of Tau Phosphorylation-Targeting Therapies for the Treatment of Neurodegenerative Diseases. Med. Plus 2024, 1 (4), 100060. https://doi.org/10.1016/j.medp.2024.100060.
18. The Multifaceted Roles of Tau: From Microtubule Stabilizer to Neurodegenerative Driver and Therapeutic Target. MedTechNews. https://medtechnews.uk/research-reports/the-multifaceted-roles-of-tau-from-microtubule-stabilizer-to-neurodegenerative-driver-and-therapeutic-target/ (accessed 2025-07-18).
19. Arranz, J.; Zhu, N.; Rubio-Guerra, S.; Rodríguez-Baz, Í.; Ferrer, R.; Carmona-Iragui, M.; Barroeta, I.; Illán-Gala, I.; Santos-Santos, M.; Fortea, J.; Lleó, A.; Tondo, M.; Alcolea, D. Diagnostic Performance of Plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE Automated Platform for the Detection of Alzheimer Disease. Alzheimers Res. Ther. 2024, 16 (1), 139. https://doi.org/10.1186/s13195-024-01513-9.
20. Mendes, A. J.; Ribaldi, F.; Lathuiliere, A.; Ashton, N. J.; Janelidze, S.; Zetterberg, H.; Scheffler, M.; Assal, F.; Garibotto, V.; Blennow, K.; Hansson, O.; Frisoni, G. B. Head-to-Head Study of Diagnostic Accuracy of Plasma and Cerebrospinal Fluid p-Tau217 versus p-Tau181 and p-Tau231 in a Memory Clinic Cohort. J. Neurol. 2024, 271 (4), 2053–2066. https://doi.org/10.1007/s00415-023-12148-5.
21. Horie, K.; Salvadó, G.; Barthélemy, N. R.; Janelidze, S.; Li, Y.; He, Y.; Saef, B.; Chen, C. D.; Jiang, H.; Strandberg, O.; Pichet Binette, A.; Palmqvist, S.; Sato, C.; Sachdev, P.; Koyama, A.; Gordon, B. A.; Benzinger, T. L. S.; Holtzman, D. M.; Morris, J. C.; Mattsson-Carlgren, N.; Stomrud, E.; Ossenkoppele, R.; Schindler, S. E.; Hansson, O.; Bateman, R. J. CSF MTBR-Tau243 Is a Specific Biomarker of Tau Tangle Pathology in Alzheimer’s Disease. Nat. Med. 2023, 29 (8), 1954–1963. https://doi.org/10.1038/s41591-023-02443-z.